Clinical trial
DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in…
NCT00389779 · Gilead Sciences, Industry · Completed
Key facts
| NCT number | NCT00389779 |
|---|---|
| Title | DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension |
| Official title | A Phase 3 Randomized, Double-Blind, Placebo- and Active-Controlled, Multi-center, Parallel Group Study to Evaluate the Safety and Efficacy of Darusentan in Subjects With Resistant Hypertension Receiving Combination Therapy With Three or More Antihypertensive Drugs, Including a Diuretic, as Compared… |
| Acronym | Darusentan |
| Lead sponsor | Gilead Sciences, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hypertension |
| Intervention type | Drug |
| Interventions | Darusentan, Guanfacine, Darusentan Placebo |
| Enrollment | 849 |
| Start date | Sep 1, 2006 |
| Primary completion | Aug 1, 2009 |
| Completion | Aug 1, 2009 |
| First posted | Oct 19, 2006 |
| Last update posted | Mar 18, 2014 |
| Countries | Argentina, Australia, Belgium, Brazil, Denmark, France, Germany, New Zealand, Spain, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: